Skip to main content

McGrath Lynne Fahey's Form 4/A amendment

Amended

Alzamend Neuro, Inc. (ALZN) · filed Apr 8, 2022

Accession no.
0001214659-22-004992
Filed
Apr 8, 2022
Trade date
Mar 28, 2022
Filing delay
11 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Apr 6, 2022

This filing lists 1 non-derivative transaction. Open-market sales total $30.3K. It was filed 11 days after the trade.

This amendment replaces 0001214659-22-004914 (filed Apr 6, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
McGrath Lynne FaheyCIK 0001866270Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 28, 2022Common StockSSaleDisposed−25,000$1.21F2−$30,25075,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The original Form 4 filed on April 6, 2022, is amended by this Form 4 amendment to correct a typographical error in Table I Column 4 from "A" to "D".

F2

The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.213. The range of sale prices on the transaction date was $1.19 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)